Amendments to the Specification

On pages 7 and 8 of the Office Action, the Examiner objects to an amendment to the specification that Applicants filed in their Preliminary Amendment of March 29, 2004. The objection is made because the amendment allegedly introduces new matter. Please cancel this amendment so that the paragraph that begins in column 1, line 61 and which continues through to column 2, line 5 remains unchanged. The changes needed to accomplish this in the paragraph as amended in the Preliminary Amendment are as follows:

> Metoclopramide is a drug known to relieve migraine-associated nausea when administered at a minimum oral dose of 10 mg. Poyser et al. have described a formulation in which ~~analgesics such as~~ aspirin~~, paracetamol or paracetamol DC are~~ is uniformly intermixed with metoclopramide (U.S. Pat. No. 4,380,540). One drawback of this formulation ~~formulations containing aspirin~~ is that[[,]] it undergoes ~~as discussed further herein, they should undergo~~ unacceptable degradation in a matter of two to three weeks at ambient temperatures. In addition, aspirin is known to have a very short plasma half life. New formulations of metoclopramide that are effective in treating migraine headache and that avoid the disadvantages of this and other previously disclosed preparations would represent a clear advance in the art.